Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05626920 · ClinicalTrials.gov registry record · Phase 1
Disulfiram for Treatment of Retinal Degeneration
A Phase 1 study of Inherited Retinal Dystrophy Primarily Involving Sensory Retina, sponsored by University of Washington.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05626920 is a Phase 1 study of Inherited Retinal Dystrophy Primarily Involving Sensory Retina that is actively recruiting participants, run by University of Washington. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05626920, a Phase 1 study of Inherited Retinal Dystrophy Primarily Involving Sensory Retina, is actively recruiting participants, sponsored by University of Washington.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Aberrant retinoic acid signaling driven by the degenerating outer retina leads to pathological changes to the inner retina. The resulting hyperactivity of retinal ganglion cells leads to further diminution of the remaining vision in those afflicted with inherited retinal diseases. Inhibition of this pathway has led to improved visual function in murine models of retinal degeneration. This can be accomplished in humans with the FDA-approved irreversible inhibitor of aldehyde dehydrogenases, disulfiram.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Disulfiram 250 mg
Study Locations (1)
Washington
- University of Washington-South Lake Union Retina Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-01-03 |
| Est. Completion | 2025-11-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05626920
The ClinicalTrials.gov registry entry for NCT05626920 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Inherited Retinal Dystrophy Primarily Involving Sensory Retina appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05626920 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT05626920 about?
NCT05626920 is a clinical study titled "Disulfiram for Treatment of Retinal Degeneration". Aberrant retinoic acid signaling driven by the degenerating outer retina leads to pathological changes to the inner retina. The resulting hyperactivity of retinal ganglion cells leads to further diminution of the remaining vision in those afflicted with inherited retinal diseases. Inhibition of this...
What is the current status of trial NCT05626920?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-01-03. Estimated completion is 2025-11-01.
What conditions does trial NCT05626920 study?
This clinical trial studies the following conditions: Inherited Retinal Dystrophy Primarily Involving Sensory Retina.
What interventions are being tested in trial NCT05626920?
The interventions under investigation include: Placebo (DRUG), Disulfiram 250 mg (DRUG).
Who is sponsoring clinical trial NCT05626920?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05626920 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.